Quantcast

Latest thyroid cancer Stories

2014-05-31 08:20:45

Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). Progression-free survival with lenvatinib was extended significantly compared to placebo (HR=0.21, [99% CI: 0.14-0.31]; p<0.0001). The median...

2014-05-19 23:04:54

Thyroid cancer increased from 14th to 5th most common cancer in women over last 20 years Fremont, California (PRWEB) May 19, 2014 The dramatic increase in the incidence of thyroid cancer worldwide over the past three decades likely relates to modifiable behavioral or environmental factors, as opposed to improved diagnostic capability, according to researchers at the Cancer Prevention Institute of California (CPIC) and their colleague at the Stanford University School of Medicine....

Scientists Seek Answers To Questions About Thyroid Cancer
2014-05-19 03:54:45

Jessica Nimon, NASA The multi-national efforts that go into research aboard the International Space Station show that working together can yield results with universal benefits. This is especially the case when talking about human health concerns such as cancer. Researchers make use of the microgravity environment aboard the space station to seek answers to questions about the nature of cancer cells. With the Microgravity on Human Thyroid Carcinoma Cells (Cellbox-Thyroid) study, recently...

2014-05-17 23:01:16

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and thyroid cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) May 17, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and other product liability claims involving a class of diabetes drugs called incretin mimetics continue to mount in a federal multidistrict litigation now underway in U.S. District Court, Southern District of...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-13 08:31:36

SOUTH SAN FRANCISCO, Calif., May 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. The Afirma Malignancy Classifiers comprise genomic tests for...

2014-05-06 08:34:15

SOUTH SAN FRANCISCO, Calif., May 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that four abstracts supporting the use of the company's Afirma Malignancy Classifiers and enhancing its overall Afirma solution will be presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific & Clinical Congress taking place May 14-18, 2014 in Las Vegas. Veracyte developed the Afirma Malignancy Classifiers to further expand the Afirma...

2014-05-02 08:24:46

SOUTH SAN FRANCISCO, Calif. and SAO PAULO, Brazil, May 2, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) and Fleury Medicine and Health today announced a new partnership that will make Veracyte's Afirma Gene Expression Classifier (GEC) available to patients in Brazil, helping to reduce unnecessary surgeries and potentially lower costs there as part of thyroid cancer diagnosis. Financial terms of the agreement were not disclosed. Through the agreement, Fleury, which has...

2014-04-23 20:23:23

WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that The Lancet published online results from the Phase 3 DECISION trial which demonstrated that NEXAVAR(®) (sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is...

2014-04-17 23:01:33

The Firm is actively evaluating Byetta lawsuit claims on behalf of diabetics who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer after taking the incretin mimetic. New York, NY (PRWEB) April 17, 2014 More than 30 federal cases have joined a federal diabetes drug litigation that includes an increasing number of Byetta lawsuit (http://www.byettalawsuit.com/) filings, as well as claims over similarly-designed medications, Bernstein Liebhard LLP reports. Court documents...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related